(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06
November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242
per share. Following this transaction holds Mr. Mathias 7.000 shares in the
company.
Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes
Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr.
Sørvoll 100.428 shares and 280,000 options in the company.
This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.
For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com